Posterior Uveitis - Pipeline Review, H1 2016

  • ID: 3743746
  • Report
  • 64 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aciont Inc.
  • Neuroptis Biotech
  • Oculis ehf
  • pSivida Corp.
  • ThromboGenics NV
  • MORE
Posterior Uveitis - Pipeline Review, H1 2016

Summary

‘Posterior Uveitis - Pipeline Review, H1 2016’, provides an overview of the Posterior Uveitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Posterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Posterior Uveitis and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Posterior Uveitis
- The report reviews pipeline therapeutics for Posterior Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Posterior Uveitis therapeutics and enlists all their major and minor projects
- The report assesses Posterior Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Posterior Uveitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Posterior Uveitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Posterior Uveitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aciont Inc.
  • Neuroptis Biotech
  • Oculis ehf
  • pSivida Corp.
  • ThromboGenics NV
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Posterior Uveitis Overview

Therapeutics Development

Pipeline Products for Posterior Uveitis - Overview

Posterior Uveitis - Therapeutics under Development by Companies

Posterior Uveitis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Posterior Uveitis - Products under Development by Companies

Posterior Uveitis - Companies Involved in Therapeutics Development

Aciont Inc.

Neuroptis Biotech

Oculis ehf

pSivida Corp.

Regeneron Pharmaceuticals, Inc.

Santen Pharmaceutical Co., Ltd.

ThromboGenics NV

Virogenomics BioDevelopment, Inc.

Posterior Uveitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

dexamethasone acetate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

dexamethasone sodium phosphate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

fluocinolone acetonide SR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NOP-3 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recombinant Peptides to Modulate TCR for Uveitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sarilumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sirolimus - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TG-931 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Posterior Uveitis - Recent Pipeline Updates

Posterior Uveitis - Dormant Projects

Posterior Uveitis - Discontinued Products

Posterior Uveitis - Product Development Milestones

Featured News & Press Releases

Mar 15, 2016: Additional Favorable Six-Month Safety Results for pSividas Medidur for Posterior Uveitis

Dec 28, 2015: pSivida Plans Medidur EU Marketing Approval Application Based on Single Phase 3 Clinical Trial

Dec 22, 2015: pSivida Medidur Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis

Sep 28, 2015: pSivida Announces NDA for Medidur Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs

May 19, 2015: pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur for Posterior Uveitis

Mar 26, 2015: pSivida Completes Targeted Enrollment of Phase III Trial of Medidur for Posterior Uveitis

Apr 15, 2013: Aciont To Present at ARVO 2013 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Posterior Uveitis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Posterior Uveitis - Pipeline by Aciont Inc., H1 2016

Posterior Uveitis - Pipeline by Neuroptis Biotech, H1 2016

Posterior Uveitis - Pipeline by Oculis ehf, H1 2016

Posterior Uveitis - Pipeline by pSivida Corp., H1 2016

Posterior Uveitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016

Posterior Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016

Posterior Uveitis - Pipeline by ThromboGenics NV, H1 2016

Posterior Uveitis - Pipeline by Virogenomics BioDevelopment, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Posterior Uveitis Therapeutics - Recent Pipeline Updates, H1 2016

Posterior Uveitis - Dormant Projects, H1 2016

Posterior Uveitis - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Posterior Uveitis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Aciont Inc.
Neuroptis Biotech
Oculis ehf
pSivida Corp.
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
ThromboGenics NV
Virogenomics BioDevelopment, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll